Pharma buying spree continues

Endo International will buy Par Pharmaceuticals for $8 billion, which will make Endo a bigger player in the fast-changing generic drug sector.

This entry was posted in Biotech & Pharmaceuticals, M&A, NBR Show Clips. Bookmark the permalink.

Leave a Reply